Vasodip Combo

Quick links to important sections

Vasodip Combo

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vasodip Combo

Vasodip Combo is a synthetic, prescription-only medication classified as an antihypertensive agent, primarily used to manage high blood pressure. It is defined as a fixed-dose combination (FDC) product, meaning it delivers two distinct active chemical entities in a single oral tablet. This formulation is clinically recognized for simplifying complex treatment regimens by integrating two medications into one pill, which is often favored to support better patient adherence.


Quick Facts

Property Description
Active ingredient Enalapril and Lercanidipine
Form Oral Tablet (Film-coated)
Pharmacological class Antihypertensive Agents (ACE Inhibitor + CCB)
Common use Management of high blood pressure (Essential Hypertension)
Origin Synthetic (Pharmaceutical synthesis)

Composition and Classification

This FDC contains two primary active ingredients: Enalapril and Lercanidipine. Enalapril is designated an Angiotensin-Converting Enzyme (ACE) Inhibitor, a class established for its systemic effects, while Lercanidipine is a distinct compound classified as a Calcium Channel Blocker (CCB). The deliberate combination ensures that two major physiological pathways contributing to high blood pressure are addressed simultaneously. The therapeutic value of combining these two distinct mechanisms for comprehensive blood pressure control is recognized.

General Purpose of This Combination Medicine

The core therapeutic purpose of Vasodip Combo is to achieve consistent and significant blood pressure (BP) reduction in individuals with essential hypertension. This FDC is typically indicated for patients whose blood pressure has not been adequately controlled by therapy with either an ACE inhibitor or a CCB used alone. By combining the two components, the medicine is designed to produce a potent synergistic antihypertensive effect, a method utilized for its reliable and sustained pressure control.

What side effects are possible with Vasodip Combo?

Possible side effects and safety information

The officially documented safety profile for this medicine, a fixed-dose combination of Enalapril (an ACE inhibitor) and Lercanidipine (a Calcium Channel Blocker), encompasses adverse reactions classified by frequency and grouped by the physiological system affected.

Frequency-Classified Adverse Reactions

The regulatory labels classify certain effects as Common (occurring in 1 to 10 out of 100 people). These may include Dizziness, Headache, Cough (a known ACE inhibitor effect), Flushing, Peripheral oedema, and Fatigue. Effects classified as Uncommon (less than 1 in 100) include Tachycardia, Palpitations, Hypotension (low blood pressure), Nausea, and Rash.


Serious Adverse Reactions and Regulatory Constraints

Official documents highlight the risk of Serious Adverse Reactions, most notably Angioedema (swelling of the face, lips, tongue, or throat) associated with the ACE inhibitor component, which is a potentially life-threatening event.

Contraindications define situations where the medicine must not be used. These include a history of Angioedema related to previous ACE inhibitor use, severe hepatic impairment, or severe renal impairment (creatinine clearance less than 30 mL/min). Use during the second and third trimesters of pregnancy is also contraindicated due to the risk of fetal toxicity. Safety information also notes that effects like Hypotension are more likely to occur at the start of treatment.

Overdose and Emergency Response

Overdose of Vasodip Combo, a fixed-dose combination of an ACE inhibitor and a Calcium Channel Blocker, primarily presents as severe hemodynamic instability. The most common clinical sign documented in regulatory documents is excessive hypotension (severely low blood pressure), often accompanied by cardiovascular changes such as bradycardia or an irregular heartbeat. Other manifestations include dizziness, sleepiness, oliguria, and progressive azotemia.

The official labels note the risk of life-threatening systemic manifestations, including acute renal failure and the rare but potentially fatal laryngeal angioedema documented with ACE inhibitors. Secondary risks, such as myocardial infarction or cerebrovascular accident, may occur due to profound blood pressure reduction. Because of these serious risks, regulatory guidance emphasizes that patients must seek immediate medical attention and go to an emergency department straight away for any suspected overdose.

No specific antidote is known for the Enalapril component, though specific reversal agents like intravenous calcium are described for Lercanidipine toxicity. Management is symptomatic and supportive, requiring hospitalisation for observation, continuous ECG monitoring, and checks for hyperkalemia and renal function. Overdose severity may be increased in those with pre-existing renal or hepatic impairment.

Therapeutic Uses of Vasodip Combo

What Vasodip Combo Treats: Main Uses and Benefits

Vasodip Combo is commonly used for managing essential hypertension, a condition characterized by periods of heightened symptoms that create noticeable physiological strain. The medication is applied across domains where additional symptomatic support is needed to help manage this systemic imbalance. This type of combination therapy is used for the treatment of hypertension.

It is relevant in clinical scenarios where symptoms may intensify temporarily, such as in patients whose blood pressure is not adequately controlled by monotherapy (a single agent), or as initial therapy when patients are likely to need multiple agents to manage conditions marked by increased physiological stress. It is typically applied to address conditions characterized by periods of heightened symptoms.

Vasodip Combo is relevant for easing symptoms related to systemic imbalance and contributes to easing the overall symptom burden. This may assist with maintaining functional stability and supports patients during episodes of heightened discomfort. The medication helps address symptom clusters that may become intense or disruptive by offering supportive relief when symptoms interfere with routine activities.

Quick Fact: May assist with managing Symptoms related to systemic imbalance

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Vasodip Combo? — Official Regulatory Information

Populations for whom use is allowed (as stated in label): Adults for whom individual components (enalapril/lercanidipine) are suitable.

Populations for whom use is not recommended (if applicable): Children and adolescents under 18 years of age; patients with mild to moderate renal or hepatic dysfunction; women who are breastfeeding; and women of child-bearing potential unless effective contraception is used.

Populations for whom use is contraindicated:

  • Individuals with known hypersensitivity or history of angioedema related to any ACE inhibitor (like enalapril) or dihydropyridine calcium channel blocker (like lercanidipine).
  • Patients with severe hepatic dysfunction or severe renal dysfunction (creatinine clearance < 30 ml/min) or those undergoing dialysis.
  • Individuals with specific heart conditions, including left ventricular outflow obstruction (e.g., aortic stenosis), untreated congestive heart failure, unstable angina pectoris, or a myocardial infarction within the last month.
  • Women who are more than 3 months pregnant (use is also not recommended during the first trimester).
  • Patients taking aliskiren (if they have diabetes or renal impairment), sacubitril/valsartan, or strong CYP3A4 inhibitors (such as certain antifungals, macrolide antibiotics, or ciclosporin).

Age-related eligibility rules: Contraindicated in children and adolescents under 18 due to lack of established safety and efficacy data. Caution is advised for elderly patients, with dosage depending on renal function.

Eligibility-related restrictions: The product is prohibited for use with grapefruit or grapefruit juice.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details officially documented drug and product interactions for the fixed-dose combination of Enalapril and Lercanidipine.

Contraindicated Combinations

Co-administration with the following products is explicitly prohibited in regulatory labeling:

  • Sacubitril/Valsartan: A mandatory separation period of at least 36 hours is required between the last dose of Sacubitril/Valsartan and the initiation of this medication.
  • Strong CYP3A4 Inhibitors: Co-administration with agents like Ketoconazole, Itraconazole, Ritonavir, and Ciclosporin is forbidden, as they significantly increase Lercanidipine plasma levels.
  • Aliskiren-containing products: Contraindicated specifically in patients with diabetes mellitus or those with documented renal impairment.

Documented Pharmacodynamic and Metabolic Interactions

Interacting Substance/Class Official Interaction Statement
Potassium-sparing Diuretics / Potassium Supplements Co-administration increases the documented risk of hyperkalemia (elevated serum potassium levels) due to the Enalapril component.
CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine) May officially reduce Lercanidipine plasma levels and, consequently, its anticipated effect.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Officially documented to increase the risk of deterioration of renal function, particularly in the elderly or those who are volume-depleted.
Lithium Co-administration with the Enalapril component is documented to increase serum lithium levels and risk of toxicity.

Non-Medicinal Product Restrictions

Grapefruit Juice and alcohol intake must be avoided, as both are officially documented to enhance the medication's systemic availability or its hypotensive effects. The medication should also be administered at least 15 minutes before a meal.

Mechanism of Action

Vasodip Combo is a dual-mechanism pharmaceutical agent targeting two distinct vascular pathways. The first component, Agent A, acts as a selective inhibitor of phosphodiesterase 5 (PDE5), an enzyme responsible for hydrolyzing cyclic guanosine monophosphate (cGMP). Inhibition of PDE5 prevents cGMP degradation, leading to elevated intracellular cGMP concentrations. This accumulation activates protein kinase G (PKG), which initiates the phosphorylation of multiple proteins that regulate the contractile state of vascular smooth muscle. The resulting cascade promotes cellular relaxation. The second component, Agent B, is a competitive antagonist of the endothelin A ( ET A) receptor. Agent B binds to this receptor, blocking the binding of the endogenous ligand, endothelin-1 (ET-1). This blockade prevents the ET A-mediated signaling cascade that induces vasoconstriction. The convergence of these two distinct actions promotes systemic vasodilation, resulting in a reduction in overall vascular resistance.

Dosage and Administration Information

How to Use Vasodip Combo

This section describes the administration and dosing guidelines for Vasodip Combo.


Administration and Scheduling

Instruction Category Guideline
Route of Administration The medication is taken orally as a film-coated tablet.
Frequency The prescribed dose is administered once daily.
Meal Timing The tablet must be taken at least 15 minutes before a meal, preferably in the morning, to ensure the intended absorption profile.
Intake Method The tablet should be swallowed whole with a glass of water and must not be chewed or crushed.

Dosing Protocol and Use Context

Vasodip Combo is a fixed-dose combination (FDC) product that is not intended for initial treatment of high blood pressure. Its use is reserved for patients whose blood pressure has not been adequately controlled by monotherapy (treatment with only one agent) using either of its components (Enalapril or Lercanidipine) at equivalent doses.

Contextual Dosing Rule Detail
Standard Dose One tablet once daily. Available strengths include 10 mg/ 10 mg and 20 mg/ 10 mg (Enalapril/Lercanidipine).
Pediatric Use The combination is not recommended for use in children and adolescents under 18 years of age, as clinical experience is lacking in this population.
Missed Dose If a dose is missed but remembered within 12 hours of the scheduled time, it should be taken. Otherwise, the missed dose is skipped, and the regular schedule resumed the next day; a compensatory double dose is not taken.

These instructions define a specific, standardized protocol for long-term administration.

Recent Clinical Evidence

Research evidence / Overview of Studies for Vasodip Combo

Evidence for Use in Managing Essential Hypertension

The Enalapril-Lercanidipine fixed-dose combination (FDC) was studied for its use in essential high blood pressure. These trials are typically short-term, randomized controlled trials (RCTs). These trials were typically applied in research contexts involving fluctuating or unstable symptoms for adult patients whose blood pressure was not adequately controlled when taking only a single blood pressure-lowering medicine. Researchers primarily examined outcomes related to physiological strain by measuring changes in both the upper (systolic) and lower (diastolic) blood pressure readings.

Studies monitored how blood pressure evolved in the observed populations compared to their starting measurements. Findings describe patterns observed in the studies where the combination regimen was associated with measured changes in blood pressure when evaluated against the individual drugs used alone. Trials reported the percentage of study participants who achieved predefined blood pressure goals for the FDC compared to the comparator groups.

Comparisons in Clinical Trials

Studies explored the use of the combination regimen against both monotherapy and placebo. Trials examining the FDC alongside monotherapy reported data related to the achievement of target blood pressure levels in comparison to the single agents alone. Furthermore, some studies exploring patient-reported outcomes describing perceived discomfort reported a difference in the incidence of peripheral swelling (an observation related to the CCB component) when compared to high-dose Lercanidipine monotherapy.

Long-Term Follow-up and Cardiovascular Endpoints

The evidence base for this specific FDC is largely derived from short-term follow-up periods. The primary efficacy trials typically observed patients for approximately 12 weeks. However, there is limited information for long-term outcomes for this specific fixed-dose combination. Therefore, long-term effects are not fully established, and information relating to the reduction of heart attack or stroke risk is generally drawn from the established findings of the individual drug classes (ACE inhibitor and calcium channel blocker) used in other, longer studies.

Research in Special Patient Groups

Studies explored the combination in older adults, and findings indicate patterns related to blood pressure change similar to those observed in the general adult population. For other groups, such as children or adolescents, data are currently limited, and dedicated studies for these populations remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Vasodip Combo (FAQ)

Q: How quickly should I expect Vasodip Combo to start lowering my blood pressure?

A: Official information indicates that the blood pressure-lowering effect from the individual components can begin within a few hours after taking the tablet. However, the maximum and most stable therapeutic benefit from the combination product typically takes about two weeks to fully appear.

Q: How long do most people have to stay on Vasodip Combo treatment?

A: This medication is generally intended for the long-term management of high blood pressure. Official prescribing information states that the treatment duration is determined by a healthcare provider based on the patient's individual condition and blood pressure control needs.

Q: Does Vasodip Combo interact with diabetes medications?

A: Regulatory documents state that this medication is explicitly prohibited from use with Aliskiren-containing products in patients who have diabetes. Additionally, one of the components has been associated with a risk of hypoglycemia (low blood sugar), suggesting potential effects that could interact with other diabetes treatment.

Q: What kind of monitoring (blood tests, etc.) is needed while on Vasodip Combo?

A: Due to the mechanisms of the active ingredients, monitoring of key health indicators may be required. Monitoring may include checks of blood pressure, kidney function, and serum potassium levels, based on individual patient need and the medication’s known effects.

Q: What is the typical time frame to see the maximum effect of Vasodip Combo?

A: The maximal blood pressure-lowering effect of the individual components typically takes about two weeks to become fully apparent. Clinical trials for this combination often monitor and establish efficacy over a period of approximately 12 weeks.

Q: Is Vasodip Combo the same as taking two separate blood pressure pills?

A: Vasodip Combo is a fixed-dose combination (FDC) that contains two different active ingredients in a single tablet. While the medications are the same, FDCs are often prescribed to simplify treatment regimens and may help improve patient adherence compared to taking two separate pills.

Q: Why is Vasodip Combo prescribed as a combination drug instead of a single ingredient?

A: Official product information states that this combination is generally reserved for patients whose high blood pressure has not been adequately controlled by therapy with either Enalapril or Lercanidipine used alone. By combining them, the medicine is designed to achieve a stronger, synergistic antihypertensive effect by addressing two distinct physiological pathways.

Q: Is it normal to feel a little dizzy when first starting Vasodip Combo?

A: Dizziness is a commonly reported side effect, according to official product information. Furthermore, the risk of low blood pressure, which can cause lightheadedness, is noted as being more likely to occur right at the start of treatment.

Q: Does Vasodip Combo interact with common cold or flu medications?

A: Regulatory documents specifically detail interactions with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which are found in some cold and flu preparations. Patients should always disclose all medications, including non-prescription products like decongestants, to their healthcare provider for review.

Q: Is there any research on the long-term effectiveness of Vasodip Combo?

A: The primary clinical evidence for this specific fixed-dose combination is derived from short-term follow-up periods, typically around 12 weeks. Therefore, long-term effects are not fully established, and information on long-term risk reduction is generally drawn from the established data on the individual drug classes.

Q: Why do doctors often switch patients to a combination pill like Vasodip Combo?

A: Official guidance indicates this medication is intended for patients who have not achieved adequate blood pressure control on a single agent. Switching to an FDC like this is a recognized strategy to intensify treatment and is often favored to simplify the dosing schedule, which may support better patient adherence.

Q: Does Vasodip Combo affect sleep or cause insomnia?

A: Insomnia (difficulty sleeping) and other sleep disorders are listed as uncommon or rare side effects in the safety profile for one of the individual components. This suggests the medication may influence sleep patterns in some people.

Q: Can taking Vasodip Combo make me feel tired or lethargic?

A: Fatigue is a commonly reported side effect listed in the official safety profile, meaning it may affect 1 to 10 out of every 100 people taking this medicine. Asthenia, a medical term for a general lack of strength or energy, is also listed as a known effect.

Q: Why does my doctor want me to take this specific 'combo' medication?

A: This medication is prescribed when blood pressure has not been sufficiently controlled by either Enalapril or Lercanidipine taken alone. By combining both in one pill, the doctor aims to utilize the synergistic effect of both mechanisms for more potent and reliable blood pressure control.

Q: What makes Vasodip Combo a different option from a single-drug therapy?

A: This medication is a fixed-dose combination (FDC) that contains two distinct pharmacological classes—an ACE Inhibitor and a Calcium Channel Blocker—in one tablet. This approach simultaneously targets two major physiological mechanisms that contribute to high blood pressure, potentially offering a stronger, combined effect than either single drug alone.

Q: Are there any known interactions between Vasodip Combo and herbal supplements?

A: Official drug safety information usually notes that herbal supplements and remedies are not tested with prescription medicines in the same way. Patients typically need to disclose all herbal products and supplements to their healthcare professional for review.

Q: Is it possible to develop a dry cough while taking Vasodip Combo?

A: A Cough is listed as a common adverse reaction, meaning it occurs in 1 to 10 out of 100 people taking this medicine. This is a known and typical effect of the ACE inhibitor component (Enalapril).

Q: What are the serious, but less common, side effects of Vasodip Combo to watch out for?

A: Serious adverse reactions highlighted in the official label include Angioedema (swelling of the face, lips, tongue, or throat). Less common but significant effects can include hypotension (overly low blood pressure) and tachycardia (a fast heart rate).

Q: Can women who are planning to become pregnant use Vasodip Combo?

A: The medication is contraindicated (must not be used) during the second and third trimesters of pregnancy due to the risk of harm to the fetus. It is generally not recommended for women who are planning to become pregnant, and women of child-bearing potential must use effective contraception while taking it.

Q: Why is proper adherence to Vasodip Combo dosage so important?

A: Proper adherence to the prescribed once-daily dose is crucial for maintaining consistent blood pressure control over the entire 24-hour period. Missed doses may lead to fluctuations in blood pressure and can compromise the goal of achieving target blood pressure levels.

Q: How do I know if the lightheadedness I feel is a normal side effect of Vasodip Combo?

A: Lightheadedness and dizziness are common, documented side effects, especially when first starting treatment. Any significant, persistent lightheadedness or feeling faint may indicate overly low blood pressure and is a symptom to be discussed with a healthcare provider.

Q: What evidence supports the use of Vasodip Combo in clinical practice?

A: Clinical trials support the use of this medication in patients whose hypertension was not adequately controlled by single-agent therapy. Studies showed that the fixed-dose combination was associated with measured reductions in blood pressure and helped patients achieve predefined blood pressure goals.

Q: Is Vasodip Combo effective for all stages of high blood pressure?

A: Official information indicates that one of the components (Lercanidipine) is specifically indicated for the treatment of mild to moderate essential hypertension. Its use in more severe or complicated forms of hypertension should be determined by a healthcare provider.

Q: Why is Vasodip Combo often taken once a day?

A: The medication is typically administered once daily because both active ingredients are formulated to provide an antihypertensive effect that is maintained for a full 24 hours. This once-daily dosing supports consistent blood pressure control.

Q: Can Vasodip Combo be used by young adults with early-onset hypertension?

A: The medication is not recommended for use in children and adolescents under 18 years of age. This is due to a lack of established safety and efficacy data in that specific population.

Q: What should I do if my skin turns red or I get a rash after taking Vasodip Combo?

A: While a minor rash is an uncommon side effect, the official label highlights the risk of a severe allergic reaction called Angioedema (swelling). Any swelling of the face, lips, tongue, or throat, or difficulty breathing, is a serious sign of Angioedema that warrants immediate medical evaluation.

Q: How does the combination of ingredients in Vasodip Combo work together?

A: The combination is designed to work synergistically. One component, an ACE inhibitor, helps widen blood vessels, while the other, a Calcium Channel Blocker, directly relaxes the vessel walls. This approach targets multiple physiological pathways that control blood pressure.

Q: Will Vasodip Combo affect my ability to drive or operate machinery?

A: Official information suggests it is unlikely to impair a patient’s ability to drive. However, caution should be exercised because documented side effects such as dizziness, fatigue, and somnolence (drowsiness) may occasionally occur and could temporarily affect concentration.

Q: Does Vasodip Combo cause problems with sexual function?

A: Impotence (inability to maintain an erection) is listed as an adverse reaction in the safety profile of the Enalapril component. This suggests the medication may, in some cases, affect sexual function.

Q: Why might a patient be considered resistant to single-drug therapy but respond to Vasodip Combo?

A: This medication is specifically designed for patients whose high blood pressure is not controlled by a single medication. By combining an ACE inhibitor and a calcium channel blocker, the drug addresses multiple underlying mechanisms of hypertension, which can be more effective than relying on a single pathway.

Q: Does Vasodip Combo interact with antacids or heartburn medicines?

A: Studies on one of the components (Lercanidipine) suggest that taking high-dose Cimetidine (an acid reducer) may require caution as it could potentially increase the medication's effect. Patients typically need to discuss all over-the-counter heartburn and antacid medicines with their healthcare provider for review.

How should Vasodip Combo be stored and disposed of?

How to Store and Dispose of Vasodip Combo?

Storage and disposal requirements are based strictly on regulatory labeling to maintain product quality and safety.


Storage Conditions

Requirement Specifics
Temperature Store at room temperature, USP (20°C to 25°C or 68°F to 77°F).
Protection Must be protected from excessive heat, light, and moisture.
Access Control Keep in a closed place and out of the reach and sight of children and/or infants.

Stability and Disposal

The medicine must not be used after the expiry date stated on the package; this refers to the last day of the stated month. Disposal of unused or expired product must be executed in accordance with local regulations. If no take-back program is available, official guidance recommends consulting national resources for proper household disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vasodip Combo found in:

A-Z Index: